| 31. |
|
|
| 32. |
|
|
| 33. |
- Carlsson, Jörgen
(författare)
-
Computational strategies in flame-spread modelling involving wooden surfaces
- 2003
-
Licentiatavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Various approaches to flame-spread and fire-growth modelling are discussed and are evaluated using experimental results from different tests. Use of Computational Fluid Dynamics, CFD, in fire modelling is discussed and the performance of different CFD codes in wall flow modelling is analysed. Different pyrolysis models are discussed with respect to their major assumptions and the input data required.
|
|
| 34. |
- Carlsson, Jörgen, et al.
(författare)
-
Conjugate chemistry and cellular processing of EGF-dextran
- 1999
-
Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 38:3, s. 313-321
-
Tidskriftsartikel (refereegranskat)abstract
- Conjugates with specific binding to the epidermal growth factor receptor, EGFR, of interest for radionuclide based imaging and therapy were prepared using mouse epidermal growth factor, mEGF, and dextran. In one type of conjugate, mEGF was coupled to dextran by reductive amination in which the free amino group on the mEGF N-terminal reacted with the aldehyde group on the reductive end of dextran. The end-end coupled conjugate could be further activated by the cyanopyridinium agent CDAP, thereby introducing tyrosines to the dextran part. In the other type of conjugate, the cyanylating procedure using CDAP was applied, first to activate dextran and then allowing for the amino terminus of mEGF to randomly attach to the dextran. In the latter case, radionuclide-labelled tyrosines or glycines could be added in the same conjugation step. All types of mEGF-dextran conjugates had EGFR-specific binding since the binding could be displaced by an excess of non-radioactive mEGF. The conjugates were to a large extent internalized in the test cells and the associated radioactivity was retained intracellularly for different times depending on both the type of cells and conjugate applied. Different intracellular 'traffic routes' for the radionuclides are discussed as well as applications for both imaging and therapy.
|
|
| 35. |
- Carlsson, Jörgen, 1944-
(författare)
-
Developmental trends in targeted radionuclide therapy : Biological aspects
- 2008
-
Ingår i: Targeted Radionuclide Tumor Therapy. - New York : Springer. - 9781402086953 ; , s. 387-398
-
Bokkapitel (populärvet., debatt m.m.)abstract
- Targeted radionuclide therapy of hematopoietic malignancies in the clinical setting has been achieved and similar successes with solid tumors and cells disseminated from them are likely within reach. Recombinant technologies have led to the development of a number of new targeting agents and the evaluation of a number of putative new targets is currently in progress. These advances are currently under evaluation in the preclinical setting and are expected to transition into clinical trials before long. Many of these new agents exhibit both improved pharmacological properties and enhanced cellular retention, both of which may lead to substantial improvements over existing compounds. In addition, our knowledge of basic radiobiology and its impact on the different modes of cell death is rapidly expanding, leading to new understanding in the fundamental differences between hematopoietic and epithelial tumor cells. Such knowledge will likely have a significant influence on the development of future treatment modalities. Furthermore, the complex interactions between radiation induced intracellular signaling pathways and the crucial observation that low dose radiation (e.g. less than 15 Gy) is able to significantly affect the growth of disseminated solid tumors cells suggests to us that a new era in targeted radionuclide therapy may soon be here.
|
|
| 36. |
- Carlsson, Jörgen
(författare)
-
Effects of low dose-rate radiation on cellular survival
- 2008
-
Ingår i: Targeted Radionuclide Tumor Therapy. - New York : Springer. - 9781402086953 ; , s. 295-310
-
Bokkapitel (populärvet., debatt m.m.)abstract
- The experience of external radiotherapy can only to a limited extent be used to understand therapeutic effects of radionuclide therapy. A major difference is that the dose-rate at radionuclide therapy is at least two orders of magnitude lower. Part of this chapter deals with estimates of the necessary dose-rate and exposure time in combination in order to deliver therapeutic effects to tumour cells. It is proposed that combinations of about 0.1–0.2 Gy/h for several days or about 1 Gy/h for at least 1 day is necessary. Such dose-rates can be achieved with the help of cross fire radiation. Effects of radionuclide therapy in terms of apoptosis, cell-cycle blocks and hyperradiosensitivity are also discussed.
|
|
| 37. |
- Carlsson, Jörgen, et al.
(författare)
-
EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides
- 2015
-
Ingår i: Radiology and Oncology. - : Walter de Gruyter GmbH. - 1318-2099 .- 1581-3207. ; 49:1, s. 50-58
-
Tidskriftsartikel (refereegranskat)abstract
- Background. There is limited effect of tyrosine kinase inhibitors or "naked" antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder canter and these methods are therefore not routinely used. Targeting radionuclides to the extracellular domain of the receptors is potentially a better possibility. Methods. EGFR- and HER2-expression was analyzed for primary tumors and corresponding metastases from 72 patients using immunohistochemistry and the internationally recommended HercepTest. Intracellular mutations were not analyzed since only the receptors were considered as targets and intracellular abnormalities should have minor effect on radiation dose. Results. EGFR was positive in 71% of the primary tumors and 69% of corresponding metastases. Local and distant metastases were EGFR-positive in 75% and 66% of the cases, respectively. The expression frequency of HER2 in related lesions was slightly higher (data from previous study). The EGFR-positive tumors expressed EGFR in metastases in 86% of the cases. The co-expression of EGFR and HER2 was 57% for tumors and 53% for metastases. Only 3% and 10% of the lesions were negative for both receptors in tumors and metastases, respectively. Thus, targeting these receptors with radionuclides might be applied for most patients. Conclusions. At least one of the EGFR- or HER2-receptors was present in most cases and co-expressed in more than half the cases. It is therefore interesting to deliver radionuclides for whole-body receptor-analysis, dosimetry and therapy. This can hopefully compensate for resistance to other therapies and more patients can hopefully be treated with curative instead of palliative intention.
|
|
| 38. |
- Carlsson, Jörgen, 1944-
(författare)
-
EGFR-family expression and implications for targeted radionuclide therapy
- 2008
-
Ingår i: Targeted Radionuclide Therapy. - New York : Springer. - 9781402086953 ; , s. 25-58
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Summary High expression in the primary tumor of receptors in the EGFR-family is most often also accompanied by a similar high expression in corresponding metastases. This makes these receptors interesting as putative targets for targeted radionuclide therapy of metastases and disseminated tumor cells. The expression of all four family members, EGFR, HER2, HER3 and HER4 is reviewed in this chapter. Studies on breast, urinary bladder, colorectal, prostate, head and neck, esophageal and glioma tumors are described and possible strategies for targeted radionuclide therapy are discussed. Quantification of receptor expression and the possible influence of genomic stability on the expression are also discussed.
|
|
| 39. |
- Carlsson, Jörgen, et al.
(författare)
-
En historia om koncernredovisning: Den Stockholm-Göteborgska drabbningen
- 2023
-
Ingår i: Balans Fördjupning.
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- Debatten om redovisningsfrågor har numera flyttat från den nationella till den internationella arenan och får inte längre så mycket utrymme i Sverige. Annorlunda var det på 1970-, 1980- och 1990-talen då inte minst tidskriften Balans utgjorde en viktig arena för samtalet om redovisningens utveckling, skriver Jörgen Carlsson och Niklas Sandell vid Ekonomihögskolan i Lund. I sin artikel lyfter de fram ett färgstarkt exempel på hur det kunde låta när svenska redovisningsspecialister debatterade koncernredovisning i början av 1990-talet.
|
|
| 40. |
|
|
